Charles Schwab Investment Management Inc. Has $374.51 Million Stake in Humana Inc. (NYSE:HUM)

Charles Schwab Investment Management Inc. lifted its holdings in Humana Inc. (NYSE:HUM) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 818,040 shares of the insurance provider’s stock after acquiring an additional 26,879 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Humana were worth $374,507,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Apollon Wealth Management LLC raised its holdings in shares of Humana by 3.9% in the fourth quarter. Apollon Wealth Management LLC now owns 3,142 shares of the insurance provider’s stock valued at $1,438,000 after buying an additional 118 shares during the last quarter. Machina Capital S.A.S. lifted its position in shares of Humana by 30.5% during the fourth quarter. Machina Capital S.A.S. now owns 3,227 shares of the insurance provider’s stock worth $1,477,000 after purchasing an additional 754 shares in the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Humana by 1.9% during the fourth quarter. Maryland State Retirement & Pension System now owns 9,724 shares of the insurance provider’s stock valued at $4,452,000 after purchasing an additional 182 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Humana by 15.0% in the fourth quarter. Private Advisor Group LLC now owns 3,339 shares of the insurance provider’s stock valued at $1,529,000 after purchasing an additional 436 shares in the last quarter. Finally, Leuthold Group LLC raised its position in Humana by 1.0% in the 4th quarter. Leuthold Group LLC now owns 18,375 shares of the insurance provider’s stock worth $8,412,000 after purchasing an additional 181 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.5 %

Shares of NYSE:HUM traded down $1.71 during midday trading on Wednesday, reaching $322.92. The company had a trading volume of 459,349 shares, compared to its average volume of 1,958,084. The business’s 50 day moving average price is $323.08 and its 200 day moving average price is $385.94. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $541.21. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The stock has a market cap of $38.91 billion, a PE ratio of 20.16, a P/E/G ratio of 1.86 and a beta of 0.49.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm earned $9.38 earnings per share. Research analysts forecast that Humana Inc. will post 16.18 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.10%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Oppenheimer lowered their target price on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Bank of America reiterated a “neutral” rating and set a $342.00 price target (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Jefferies Financial Group cut their price objective on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a report on Monday, April 22nd. Cantor Fitzgerald reduced their price target on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Finally, StockNews.com cut Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 26th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Humana has a consensus rating of “Hold” and a consensus target price of $424.50.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita bought 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.29% of the stock is owned by insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.